Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis

References

• Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Lambourne J, Marta M, Turner B, Gnanapavan S, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020;20(6):435–6. doi:10.1136/practneurol-2020-002527.
   PubMedGoogle Scholar
• Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68:1267–71.
   PubMedGoogle Scholar
• Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001;344(5):319–26. doi:10.1056/NEJM200102013440501.
   PubMed Web of Science ®Google Scholar
• Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017;264:1035–50. doi:10.1007/s00415-016-8263-4.
   PubMed Web of Science ®Google Scholar
• Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258:1197–206. doi:10.1007/s00415-011-5984-2.
   PubMed Web of Science ®Google Scholar
• Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler. 2021;27:864–70.
   PubMed Web of Science ®Google Scholar
• Ali Sahraian M, Ghadiri F, Azimi A, Naser Moghadasi A. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine. 2021;39:6347–50. doi:10.1016/j.vaccine.2021.09.030.
   PubMed Web of Science ®Google Scholar
• Lotan I, Wilf‐yarkoni A, Friedman Y, Stiebel‐kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. Eur J Neurol. 2021;28(11):3742–48. doi:10.1111/ene.15028.
   PubMed Web of Science ®Google Scholar
• Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, and De Giglio L, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021. doi:10.1007/s13311-021-01165-9.
   PubMed Web of Science ®Google Scholar
• Alonso R, Chertcoff A, Leguizamón FDV, Galleguillos Goiry L, Eizaguirre MB, Rodríguez R, Sosa M, Carballido S, Cruchet V, de Jong-Martis A, et al. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. Mult Scler J Exp Transl Clin. 2021;7:20552173211061543.
   Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73. doi:10.1016/S1474-4422(17)30470-2.
   PubMed Web of Science ®Google Scholar
• Allen-Philbey K, Stennett A, Begum T, Johnson A, Dobson R, Giovannoni G, Gnanapavan S, Marta M, Smets I, Turner BP, et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord. 2021;52:103028.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–21. e9. doi:10.1016/j.cell.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51. doi:10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, Nourwali I, Qasem F, Dar-Odeh N. Side effects reported by Jordanian healthcare workers who received COVID-19 vaccines. Vaccines. 2021;9:577.
   Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, et al. Effect of 2 Inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. Jama. 2021;326(1):35. doi:10.1001/jama.2021.8565.
   PubMed Web of Science ®Google Scholar
• Olberg H, Eide G, Cox R, Jul‐larsen Å, Lartey S, Vedeler C, Myhr K-M. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25(3):527–34. doi:10.1111/ene.13537.
   PubMed Web of Science ®Google Scholar
• Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, Zettl UK. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies. CNS Neurosci Ther. 2019;25(2):245–54. doi:10.1111/cns.13034.
   PubMed Web of Science ®Google Scholar
• Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341:22–27.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Nouri H, Pitzalis M, Idda ML, Salari M, Baratian M, Mahdavi S, Abhari AP, and Sedaghat N. 13 2 2022. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis. doi:10.1101/2022.02.12.22270883
   Google Scholar
• Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835.
   Web of Science ®Google Scholar
• Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, Da Rin G, Serrati C, Gandoglia I, Tassinari T, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;103581. doi:10.1016/j.ebiom.2021.103581
   PubMed Web of Science ®Google Scholar
• Chilimuri S, Mantri N, Gongati S, Zahid M, Sun H. COVID-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab. Vaccines. 2021;9:219. doi:10.3390/vaccines9030219.
   PubMed Web of Science ®Google Scholar
• Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, Fantozzi R. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult Scler Relat Disord. 2021;52:102983. doi:10.1016/j.msard.2021.102983.
   PubMed Web of Science ®Google Scholar
• Gallo A, Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, dʻAmbrosio A, Coppola N, Galdiero M, and Tedeschi G. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. Neuro Sci. 2021;42:3523–3526. doi:10.1007/s10072-021-05397-7.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Sigari AA, Sedaghat N, Salari M, and Nouri H. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Hum Vaccin Immunother. 2021;17(10):3481–3483. doi:10.1080/21645515.2021.1928463.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Sedaghat N, Nouri H, Lotfi N, Chitsaz A, Khorvash R, Zolfaghari H, Ghasemi Movaghar A, Pourabbas M, and Salari M. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: same story, different vaccine. Mult Scler Relat Disord. 2022;57: 103417. doi:10.1016/j.msard.2021.103417.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Schiavetti I, Inglese M, Carmisciano L, Laroni A, Lapucci C, Visconti V, Serrati C, Gandoglia I, Tassinari T, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies. medRxiv 2021.
   Google Scholar
• Etemadifar M, Abhari AP, Nouri H, Eighani N, Salari M, and Sedaghat N. Effect of disease-modifying therapies on clinical efficacy of COVID-19 inactivated vaccination among people with multiple sclerosis doi:10.2139/ssrn.3998537. Available at SSRN 3998537 2022.
   Google Scholar